세계의 Lab-on-a-chip 시장 예측(-2032년) : 제품, 재료, 기술, 용도, 최종 사용자, 지역별 분석

According to Stratistics MRC, the Global Lab-on-a-chip Market is accounted for $7.3 billion in 2025 and is expected to reach $15.5 billion by 2032 growing at a CAGR of 11.3% during the forecast period. Lab-on-a-chip is a compact analytical device that integrates multiple laboratory processes into a single microfluidic platform. Designed for efficiency, these systems enable rapid biochemical and molecular analysis with minimal sample requirements. By streamlining diagnostic procedures, drug testing, and environmental monitoring, they optimize resource consumption while delivering precise results. Their automated functionality and real-time detection capabilities enhance biomedical research and point-of-care applications.

Market Dynamics:

Driver:

Growing demand for point-of-care (POC) diagnostics

The miniaturized analytical devices offer rapid, precise testing, eliminating the need for extensive laboratory procedures and facilitating immediate medical decisions. With rising prevalence of chronic diseases, clinicians require efficient diagnostic solutions that ensure timely interventions. Lab-on-a-chip systems provide cost-effective, user-friendly alternatives to conventional diagnostic methods, making them indispensable in remote and decentralized healthcare settings.

Restraint:

Complex design and fabrication challenges

Advanced microfluidic systems require precise engineering and specialized materials, increasing development costs. The integration of multiple laboratory functions on a single chip demands high manufacturing accuracy, creating barriers for mass production. Additionally, ensuring compatibility with existing diagnostic workflows presents technical difficulties which hampers the market growth.

Opportunity:

Emerging organ-on-a-chip and human-on-a-chip models

Emerging innovative platforms replicate physiological conditions, allowing researchers to study disease mechanisms and therapeutic responses more efficiently. Lab-on-a-chip devices equipped with microengineered tissues offer predictive insights into drug efficacy, reducing dependency on animal testing. Pharmaceutical companies and research institutions are investing in advanced chip-based models to accelerate clinical trials and personalized medicine initiatives.

Threat:

Competition from traditional lab instruments

Competition from traditional laboratory instruments poses a challenge to lab-on-a-chip adoption in certain sectors. Established diagnostic tools, such as centralized analyzers and automated lab systems, continue to dominate clinical settings due to their high throughput and standardized protocols. Healthcare providers may hesitate to shift towards chip-based platforms, citing concerns about accuracy, regulatory approvals, and integration with existing infrastructure.

Covid-19 Impact:

The pandemic underscored the significance of rapid and decentralized diagnostics, boosting interest in lab-on-a-chip technology. Demand surged for portable testing solutions that could detect infections efficiently, reducing reliance on centralized laboratories. Research efforts accelerated to develop COVID-19 diagnostic chips with high sensitivity and speed, improving disease surveillance capabilities. However, supply chain disruptions affected manufacturing timelines, temporarily slowing market expansion.

The reagents & consumables segment is expected to be the largest during the forecast period

The reagents & consumables segment is expected to account for the largest market share during the forecast period driven by consistent demand for essential chemical components in lab-on-a-chip operations. These materials facilitate sample preparation, biochemical reactions, and analytical processes within microfluidic systems. The expanding use of lab-on-a-chip devices in diagnostic laboratories, pharmaceutical research, and environmental monitoring reinforces steady growth in reagent consumption.

The microfluidics technology segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the microfluidics technology segment is predicted to witness the highest growth rate fueled by advancements in chip-based analytical systems. Microfluidic innovations optimize fluid handling, reaction kinetics, and multiplexed testing, improving diagnostic accuracy and efficiency. The integration of nanotechnology and AI-driven automation further enhances microfluidic capabilities, expanding its role in biomedical applications.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share attributed to strong healthcare infrastructure, extensive research investments, and widespread adoption of advanced diagnostics. The region's emphasis on precision medicine and decentralized testing contributes to the prominence of lab-on-a-chip solutions in clinical and pharmaceutical settings. Regulatory support and ongoing innovation in microfluidics further reinforce North America's leadership in the global market.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR propelled by increasing healthcare access, technological advancements, and growing biomedical research initiatives. Government funding for diagnostics innovation and the rise of personalized medicine are stimulating demand for lab-on-a-chip technology. Expanding biotech industries, particularly in China, Japan, and India, are driving market growth, positioning Asia Pacific as a dynamic hub for next-generation diagnostic development.

Key players in the market

Some of the key players in Lab-on-a-chip Market include Becton, Dickinson and Company, PerkinElmer, Inc., Bio-Rad Laboratories, Agilent Technologies, Inc., Thermo Fisher Scientific, Siemens Healthcare, Abaxis Inc., Roche Diagnostics, Abbott Laboratories, Danaher Corporation, Fluidigm Corporation, Micronit BV, Illumina Inc., Phalanx Biotech Group Inc., bioMerieux SA, Qiagen NV, Merck KGaA, Cepheid Inc., and IDEX Corporation.

Key Developments:

In May 2025, Thermo Fisher Scientific introduced next-generation MS platforms delivering up to 35% faster scan speed and 50% higher multiplexing capacity to accelerate multi-omics and precision medicine research. These tools enhance Thermo Fisher's proteomics portfolio and support breakthroughs in cancer and Alzheimer's studies.

In May 2025, Illumina Inc. Launched DRAGEN v4.4 with enhanced structural variant detection (~30% improvement), new oncology apps, and AWS F2 cloud support. This update improves performance and scalability for clinical and research-grade genomic pipelines.

In May 2025, Danaher Corporation announced a collaboration to develop AI-powered diagnostics and digital tools to enhance clinical insights and patient outcomes. This partnership bridges Danaher's diagnostics reach with AstraZeneca's therapeutic expertise

Products Covered:

• Reagents & Consumables
• Instruments
• Software & Services

Materials Covered:

• Polymers
• Glass
• Silicon
• Paper
• Other Materials

Technologies Covered:

• Microfluidics Technology
• Optical Technology
• Electrochemical Technology
• Microarrays
• Tissue Biochip / Organ-on-a-chip
• Other Technologies

Applications Covered:

• Clinical Diagnostics
• Drug Discovery & Development
• Genomics & Proteomics
• Environmental Monitoring
• Food Safety & Quality Control
• Other Applications

End Users Covered:

• Hospitals & Diagnostic Centers
• Biotechnology & Pharmaceutical Companies
• Academic & Research Institutes
• Forensic Laboratories
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Technology Analysis
• 3.8 Application Analysis
• 3.9 End User Analysis
• 3.10 Emerging Markets
• 3.11 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Lab-on-a-chip Market, By Product

• 5.1 Introduction
• 5.2 Reagents & Consumables
  • 5.2.1 Microfluidic Chips/Cartridges
  • 5.2.2 Beads & Particles
  • 5.2.3 Detection Reagents
  • 5.2.4 Buffers & Solutions
• 5.3 Instruments
  • 5.3.1 Sample Preparation Units
  • 5.3.2 Integrated LOC Systems
  • 5.3.3 Accessories
• 5.4 Software & Services
  • 5.4.1 Data Analysis Software
  • 5.4.2 Automation & Control Software
  • 5.4.3 Cloud-based Solutions
  • 5.4.4 Custom Chip Design & Fabrication Services
  • 5.4.5 Maintenance & Support Services
  • 5.4.6 Training & Consultation Services

6 Global Lab-on-a-chip Market, By Material

• 6.1 Introduction
• 6.2 Polymers
• 6.3 Glass
• 6.4 Silicon
• 6.5 Paper
• 6.6 Other Materials

7 Global Lab-on-a-chip Market, By Technology

• 7.1 Introduction
• 7.2 Microfluidics Technology
• 7.3 Optical Technology
• 7.4 Electrochemical Technology
• 7.5 Microarrays
• 7.6 Tissue Biochip / Organ-on-a-chip
• 7.7 Other Technologies

8 Global Lab-on-a-chip Market, By Application

• 8.1 Introduction
• 8.2 Clinical Diagnostics
• 8.3 Drug Discovery & Development
• 8.4 Genomics & Proteomics
• 8.5 Environmental Monitoring
• 8.6 Food Safety & Quality Control
• 8.7 Other Applications

9 Global Lab-on-a-chip Market, By End User

• 9.1 Introduction
• 9.2 Hospitals & Diagnostic Centers
• 9.3 Biotechnology & Pharmaceutical Companies
• 9.4 Academic & Research Institutes
• 9.5 Forensic Laboratories
• 9.6 Other End Users

10 Global Lab-on-a-chip Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Becton, Dickinson and Company
• 12.2 PerkinElmer, Inc.
• 12.3 Bio-Rad Laboratories
• 12.4 Agilent Technologies, Inc.
• 12.5 Thermo Fisher Scientific
• 12.6 Siemens Healthcare
• 12.7 Abaxis Inc.
• 12.8 Roche Diagnostics
• 12.9 Abbott Laboratories
• 12.10 Danaher Corporation
• 12.11 Fluidigm Corporation
• 12.12 Micronit BV
• 12.13 Illumina Inc.
• 12.14 Phalanx Biotech Group Inc.
• 12.15 bioMerieux SA
• 12.16 Qiagen NV
• 12.17 Merck KGaA
• 12.18 Cepheid Inc.
• 12.19 IDEX Corporation